Gene · 148
Papers1,657
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,657
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Understanding the Impact of Sustainable Pharmaceutical Packaging on the Chemical Stability of Silodosin. | Pharmaceutics | 2025 | 41471063 | PubTator, text mining | PubMed |
| The study on potential pharmacological mechanism of semen strychny against glioma via network pharmacology analysis, molecular docking, and experimental verification. | Medicine (Baltimore) | 2025 | 41430985 | PubTator, text mining | PubMed |
| Silodosin in treating men With BPH-associated lower urinary tract Symptoms: A systematic review and network meta-analysis. | Int J Surg | 2025 | 41346266 | PubTator, text mining | PubMed |
| Induction of apoptosis and growth inhibition by silodosin and abiraterone acetate in PC-3 human prostate cancer cells. | Investig Clin Urol | 2025 | 41184150 | PubTator, text mining | PubMed |
| α1A-Adrenergic Receptor as a Target for Neurocognition: Cautionary Tale from Nicergoline and Quinazoline Non-Selective Blockers. | Pharmaceuticals (Basel) | 2025 | 41155541 | PubTator, text mining | PubMed |
| The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. | Biomolecules | 2025 | 41154665 | PubTator, text mining | PubMed |
| Polyclonal immunoglobulin G deposits with distinctive appearance in the tubular basement membrane: a report of two cases. | BMC Nephrol | 2025 | 41146073 | PubTator, text mining | PubMed |
| Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management. | J Pers Med | 2025 | 40863448 | PubTator, text mining | PubMed |
| Study on differentially expressed genes and pattern recognition receptors in osteoporosis based on bioinformatics analysis. | Sci Rep | 2025 | 40854963 | PubTator, text mining | PubMed |
| Acridocarpus smeathmannii root extracts inhibit human prostate and bladder smooth muscle contraction, porcine arterial vasoconstriction, and cytotoxicity of prostate stromal cells. | Front Pharmacol | 2025 | 40766755 | PubTator, text mining | PubMed |
| Drug-target interaction prediction based on graph convolutional autoencoder with dynamic weighting residual GCN. | BMC Bioinformatics | 2025 | 40731315 | PubTator, text mining | PubMed |
| The topology of molecular representations and its influence on machine learning performance. | J Cheminform | 2025 | 40691856 | PubTator, text mining | PubMed |
| Molecular mechanism of human α1A-adrenoceptor inhibition by Mamba snake toxin AdTx1. | Commun Biol | 2025 | 40670604 | PubTator, text mining | PubMed |
| GPCR-A17 MAAP: mapping modulators, agonists, and antagonists to predict the next bioactive target. | J Cheminform | 2025 | 40646657 | PubTator, text mining | PubMed |
| A Comprehensive Review of the Clinical Evidence on the Efficacy, Effectiveness, and Safety of Silodosin for the Treatment of Benign Prostatic Hyperplasia. | Cureus | 2025 | 40621239 | PubTator, text mining | PubMed |
| GraphAge: Unleashing the power of graph neural network to decode epigenetic aging. | PNAS Nexus | 2025 | 40583914 | PubTator, text mining | PubMed |
Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry. | Arch Toxicol | 2025 | 40178592 | PubTator, text mining | PubMed |
| Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of Mild to Moderate Facial Rosacea. | J Cosmet Dermatol | 2025 | 40165547 | PubTator, text mining | PubMed |
| Mechanism of action of aloperine in the treatment of pulmonary arterial hypertension based on network pharmacology and molecular docking methods. | Herz | 2025 | 40055190 | PubTator, text mining | PubMed |
| Improving drug repositioning accuracy using non-negative matrix tri-factorization. | Sci Rep | 2025 | 40050702 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/148/papers?page=2